111In-pentetreotide scintigraphy in medulloblastoma

Basit Öğe Kaydı
dc.authorwosidEzziddin, Samer/E-8406-2014
dc.contributor.authorYuksel, Mahmut
dc.contributor.authorLutterbey, Gotz
dc.contributor.authorBiersack, Hans Juergen
dc.contributor.authorElke, Urs
dc.contributor.authorHasan, Carola
dc.contributor.authorGao, Zairong
dc.contributor.authorBode, Udo
dc.date.accessioned2024-06-12T11:17:48Z
dc.date.available2024-06-12T11:17:48Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractMedulloblastoma (MB) is a primitive neuroectodermal tumour constituting a grade IV brain malignancy. Early and correct detection of recurrence or metastasis is desirable for follow-up of patients in this entity. Frequent expression of somatostatin receptors by MB lesions facilitates functional tumour imaging by somatostatin receptor scintigraphy (SRS). To investigate the value of SRS in the follow-up of MB, the results of ten consecutive patients (seven children and three adults) undergoing additional imaging with In-111-pentetreotide were reviewed. Four, 24 and 48 h p.i. planar and whole body images as well as a SPECT study at 4 h p.i. were acquired after intravenous injection of 109 +/- 35 MBq In-111-pentetreotide (Octreoscan). SRS yielded 11 positive and ten negative imaging results, compared to 17 positive and four negative in magnetic resonance imaging (MRI). The lesion-by-lesion analysis with a total of 44 lesions revealed a sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 42%, 83%, 94%, 18% for SRS and 89.5%, 50%, 92%, 43% for MRI. Based on a per-patient analysis, considering the patient as to be either tumour-free or tumour-positive by one imaging modality, the following values for sensitivity, specificity, PPV and NPV were obtained: 61%, 100%, 100%, 30% for SRS and 94%, 67%, 94%, 67% for MRI. MRI remains the first step imaging technique in medulloblastoma patients before and after surgery and during the follow-up providing the highest sensitivity. However, to improve specificity and contribute to correct diagnosis in MB In-111-pentetreotide scintigraphy should be considered as a confirmatory second step imaging tool, especially in case of equivocal MRI results. Moreover, a positive SRS scan might serve as a reference before and after somatostatin receptor targeted radiotherapy.en_US
dc.identifier.doi10.1080/02841860600833152
dc.identifier.endpage117en_US
dc.identifier.issn0284-186X
dc.identifier.issue1en_US
dc.identifier.pmid17438713en_US
dc.identifier.scopus2-s2.0-33847050908en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage111en_US
dc.identifier.urihttps://doi.org/10.1080/02841860600833152
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24850
dc.identifier.volume46en_US
dc.identifier.wosWOS:000244179700015en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Asen_US
dc.relation.ispartofActa Oncologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCentral-Nervous-Systemen_US
dc.subjectSomatostatin Receptor Scintigraphyen_US
dc.subjectDiagnosed Malignant Gliomasen_US
dc.subjectPediatric Brain-Tumorsen_US
dc.subjectHigh-Dose Chemotherapyen_US
dc.subjectRecurrent Medulloblastomaen_US
dc.subjectFollow-Upen_US
dc.subjectChildhooden_US
dc.subjectChildrenen_US
dc.subjectMren_US
dc.title111In-pentetreotide scintigraphy in medulloblastomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu